MedDataX Logo

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

NCT ID: NCT00197834

Last Updated: 2006-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, naturalistic, open label study will test the hypothesis that Depakote is correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and physical agitation and aggression scales over a 6-week period among patients with elevated scores on those scales, and that these positive results can be achieved with fewer side effects than with other agents. In addition, patients will be rated with respect to changes in the Clinical Global Impression (CGI) at baseline, week 1, 3, and 6 and the Neuropsychiatric Inventory (NPI) at baseline and week 6.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This open label, naturalistic study will enroll a total of 20 patients who are being treated for Behavioral and Psychological Symptoms of Dementia (BPSD), and who are being newly tried on Depakote in either the ER or sprinkle formulation. Patients who are suitable for study inclusion will have a score of at least 4 (out of 5, with 5 being the most severe) on at least one item (verbal agitation, physical agitation, and or aggression) of the Cohen-Mansfield Agitation Inventory (CMAI), short form. In this study Depakote ER will be prescribed in addition to existing pharmacotherapy; there will be no washout of co-prescribed psychotropic agents. The study will not seek to enroll equal numbers of patients on Depakote only vs. concomitant treatment. Study subjects will be recruited in multiple assisted living, nursing home and hospital sites in Massachusetts. We anticipate that they will roughly mirror the age, gender, and other demographic distribution of the larger SCU population. This will be a rolling enrollment as patients present with symptoms appropriate for this treatment. Our estimate is based on past experience with the referral rates for medication evaluation from these sites. Patients currently on atypical antipsychotics who have residual BPSD will be considered for the study, as will those on acetylcholinesterase inhibitors. Our logic is that as prescribed, these agents are not having the desired effect in reducing BPSD. Patients who are taking, and are appropriate to remain on, conventional antipsychotics will be excluded from the study. For each enrolled patient we will obtain baseline a psychiatric and medical assessment; results of the Mini Mental Status Evaluation (MMSE), CMAI, NPI - NH version and CGI; and a nursing staff patient status report prior to beginning psychotropic medication. These will be completed at time of study enrollment. Patients will then be followed for six weeks, with valproic acid levels drawn at weeks 1,3, and 6. Nursing staff will complete the CMAI at baseline and at weeks 1, 3, and 6. Physicians will score patients on the CGI at baseline, week 1, 3, and 6, and Clinical Raters will complete the NPI at baseline and week 6.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Depakote Agitation Dementia Atypical antipsychotic Behavioral Symptoms Psychiatric Symptoms Psychological Symptoms Geriatric Behavioral and Psychological Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Depakote

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) dementia diagnosis
* Age \> or = 60 years
* MMSE \> 7
* Clinical evidence of a behavioral disturbance as evidenced by nursing staff report or mean score of \> 4 on at least one CMAI item
* May be on and remain on co-prescribed psychotropic agents (e.g., antidepressants, atypical antipsychotics, acetylcholinesterase inhibitors)

Exclusion Criteria

* Patients with schizophrenia, bipolar disorder, seizure disorder that are co-morbid with dementia
* Patients with delirium, or a poorly controlled medical illness
* MMSE \> 24
* Lack of a significant behavioral disturbance
* Low platelet count
* Liver function tests (LFTs) \> 2x normal
* Currently on a Depakote formulation or prior unsuccessful trial of Depakote
* Currently on lamotrigine (Lamictal)
* Not currently on but intends to initiate treatment with an acetylcholinesterase inhibitor or memantine during the course of the study.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott

INDUSTRY

Sponsor Role collaborator

Hearthstone Alzheimer Care

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Vanelli, MD

Role: PRINCIPAL_INVESTIGATOR

Hearthstone Alzheimer Care

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hearthstone at Golden Pond

Hopkinton, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Joan Hyde, Ph.D.

Role: CONTACT

Phone: 781-674-2884

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mark Vanelli, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NEIRB05032

Identifier Type: -

Identifier Source: org_study_id